Albireo Pharma, Inc.

Good afternoon and welcome to the Albarrio Pharma third quarter 2022 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the call, please press star then zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the call over to your host, Hans Witzem, Managing Director of LifeSci Advisors. Thank you, you may begin.

Thank you, operator. This afternoon, Albareo issued a press release highlighting its recent business accomplishments and financial results for the third quarter ended September 30th, 2022. This press release is accessible via the company's website at albareopharma.com. Before proceeding, we would like to note that the management's comments today may include forward-looking statements regarding the company's plans and expectations. These statements are being made under the Private Securities Litigation Reform Act of 1995, and they are subject to various risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk factors section of the company's most recent Form 10-K and subsequent SEC filings. These filings can be accessed from the investor section at albareofarma.com or on the SEC's website. Any forward-looking statements represent our views as of today, November 8, 2022, and should not be relied upon as representing our views as of any subsequent dates. We undertake no obligation to publicly update these statements. Now, it is my pleasure to turn the call over to Ron Cooper, Albareo's President and Chief Executive Officer. Ron?

Well, thanks, Hans. And thank you all for joining us this afternoon. With me today are Dr. Jan Motsen, Chief Scientific Officer and Head of R&D, Pamela Stevenson, our Chief Commercial Officer, and Simon Hartford, our Chief Financial Officer. It's been another significant quarter for Alvareo as we continue to develop our lead product, Bilvey, to reach its full potential. We're moving fast to strengthen the valuability both on the clinical evidence front and on the commercial front. Revenues have accelerated this quarter, which is exciting as we anticipate gaining access to more patients in additional diseases. We're also excited to present new top quality data at the AASLD deliver meeting this past weekend. Let me turn it over to Jan to give you an update on the data and our studies. Jan? Thanks, Ron.